{"entity":{"id":"nct07087158","kind":"trial","name":"A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma","aka":[],"tldr":"A phase 2 trial of Pazopanib in renal cell carcinoma, run by Imbioray (Hangzhou) Biomedicine Co., Ltd., now recruiting.","summary":"A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma is a phase 2 interventional study registered as NCT07087158 by Imbioray (Hangzhou) Biomedicine Co., Ltd., with 30 participants planned, started 2025-09-08 and due to reach its primary completion in 2026-12-31. Interventions recorded: IBR854, Pazopanib. Conditions listed: Renal Cell Carcinoma (RCC). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07087158","url":"https://clinicaltrials.gov/study/NCT07087158"}],"tags":["ctgov-ingest"],"related":[],"cancers":["rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["pazopanib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07087158","phase":"2","setting":"A Multicenter, Randomized, Open-Label, Active-Controlled Phase II Study Evaluating the Efficacy and Safety of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma","sponsor":"Imbioray (Hangzhou) Biomedicine Co., Ltd.","enrolled":30,"outcomes":[]},"route":"/trials/nct07087158/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"drug":[{"id":"pazopanib","kind":"drug","name":"Pazopanib","route":"/drugs/pazopanib/"}]}}